Back to Search Start Over

De novo mutations in the GTP/GDP-binding region of RALA, a RAS-like small GTPase, cause intellectual disability and developmental delay.

Authors :
Susan M Hiatt
Matthew B Neu
Ryne C Ramaker
Andrew A Hardigan
Jeremy W Prokop
Miroslava Hancarova
Darina Prchalova
Marketa Havlovicova
Jan Prchal
Viktor Stranecky
Dwight K C Yim
Zöe Powis
Boris Keren
Caroline Nava
Cyril Mignot
Marlene Rio
Anya Revah-Politi
Parisa Hemati
Nicholas Stong
Alejandro D Iglesias
Sharon F Suchy
Rebecca Willaert
Ingrid M Wentzensen
Patricia G Wheeler
Lauren Brick
Mariya Kozenko
Anna C E Hurst
James W Wheless
Yves Lacassie
Richard M Myers
Gregory S Barsh
Zdenek Sedlacek
Gregory M Cooper
Source :
PLoS Genetics, Vol 14, Iss 11, p e1007671 (2018)
Publication Year :
2018
Publisher :
Public Library of Science (PLoS), 2018.

Abstract

Mutations that alter signaling of RAS/MAPK-family proteins give rise to a group of Mendelian diseases known as RASopathies. However, among RASopathies, the matrix of genotype-phenotype relationships is still incomplete, in part because there are many RAS-related proteins and in part because the phenotypic consequences may be variable and/or pleiotropic. Here, we describe a cohort of ten cases, drawn from six clinical sites and over 16,000 sequenced probands, with de novo protein-altering variation in RALA, a RAS-like small GTPase. All probands present with speech and motor delays, and most have intellectual disability, low weight, short stature, and facial dysmorphism. The observed rate of de novo RALA variants in affected probands is significantly higher (p = 4.93 x 10(-11)) than expected from the estimated random mutation rate. Further, all de novo variants described here affect residues within the GTP/GDP-binding region of RALA; in fact, six alleles arose at only two codons, Val25 and Lys128. The affected residues are highly conserved across both RAL- and RAS-family genes, are devoid of variation in large human population datasets, and several are homologous to positions at which disease-associated variants have been observed in other GTPase genes. We directly assayed GTP hydrolysis and RALA effector-protein binding of the observed variants, and found that all but one tested variant significantly reduced both activities compared to wild-type. The one exception, S157A, reduced GTP hydrolysis but significantly increased RALA-effector binding, an observation similar to that seen for oncogenic RAS variants. These results show the power of data sharing for the interpretation and analysis of rare variation, expand the spectrum of molecular causes of developmental disability to include RALA, and provide additional insight into the pathogenesis of human disease caused by mutations in small GTPases.

Subjects

Subjects :
Genetics
QH426-470

Details

Language :
English
ISSN :
15537390 and 15537404
Volume :
14
Issue :
11
Database :
Directory of Open Access Journals
Journal :
PLoS Genetics
Publication Type :
Academic Journal
Accession number :
edsdoj.93967530c8af4c5fa8d3a8dbcc7ae4f4
Document Type :
article
Full Text :
https://doi.org/10.1371/journal.pgen.1007671